DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Obeticholic acid
Obeticholic acid
New Brunswick Drug Plans Formulary
Supplementary Information
OCALIVA™ (Obeticholic Acid) Oral
Ocaliva (Obeticholic Acid)
An Update on the Management of Cholestatic Liver Diseases
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Obeticholic Acid and 46% of the 5–10 Mg Group
FXR Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux
Commissioner Final Decisions
New to Market Drugs Prior Authorization Criteria
Emerging Therapies for PBC
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 2 3 4 5 Keith D
DSC for Ocaliva (Obeticholic Acid)
Obeticholic Acid (Ocaliva) Reference Number: ERX.SPA.174 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
Metabolic Pharmacotherapy for NAFLD/NASH
Highlights of FDA Activities – 2/1/18 – 2/28/18
Drug-Induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post-Market Setting
Antifibrotics in Liver Disease: Are We Getting Closer to Clinical Use?
Top View
OCALIVA, INN-Obeticholic Acid
207999Orig1s000
OCALIVA (Obeticholic Acid)
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Angiogenesis As a Potential Therapeutic Target for NASH Treatment
Obeticholic Acid: First Global Approval
Future Medical Treatment of PSC
Novel Therapies for Primary Sclerosing Cholangitis
Gastrointestinal Drug Advisory Committee (GIDAC) Meeting
Protein–Ligand Binding with the Coarse-Grained Martini Model
Nanomedicine: a New Therapeutic Approach in Liver Diseases
Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin
Obeticholic Acid (Ocaliva®) Policy #: Rx.01.186
Klasifikacija ATC 2019
Ocaliva (Obeticholic Acid) Prior Authorization with Quantity Limit
Current Management and Future Treatment of Alcoholic Hepatitis
Obeticholic Acid (Ocaliva®)
Dostupnost Léčiv Pro Trávicí Trakt a Metabolická Onemocnění: Kouzlo
OCALIVA (Obeticholic Acid) Tablets Page 1 of 30
Downloaded from the Protein Data Bank (PDB ID: 6VSB)
New Brunswick Drug Plans Formulary
WHO Drug Information Vol
(NASH): Review of Phase 2 and 3 Trials
The Risks of Liver Injury in COVID-19 Patients and Pharmacological
The Asia–Pacific Working Party on Non-Alcoholic Fatty Liver Disease
CHANGES to the HIGHMARK DRUG FORMULARIES Following Is the Fourth Quarter 2016 Update to the Highmark Drug Formularies and Pharmaceutical Management Procedures
World Journal of Hepatology
Obeticholic Acid: a New Era in the Treatment of Nonalcoholic Fatty Liver Disease
EASL Clinical Practice Guidelines: the Diagnosis and Management of Patients with Primary Biliary Cholangitisq
Bile Salts Summary – December 2019 Page 2 | Proprietary Information
Ocaliva (Obeticholic Acid) NOTICE
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Potent Natural Products and Herbal Medicines for Treating Liver Fibrosis Shao-Ru Chen, Xiu-Ping Chen, Jin-Jian Lu, Ying Wang* and Yi-Tao Wang*
New Mechanistic Insights Into Hepatoprotective Activity of Milk Thistle and Chicory Quantified Extract: the Role of Hepatic Farnesoid-X Activated Receptors
Pharmacy Medical Necessity Guidelines: Ocalivatm (Obeticholic Acid) Effective: November 10, 2020
Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases Via Network Endopharmacology
Sequential Drug Delivery for Liver Diseases
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WHO Pharmaceuticals Newsletters
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need 1 2 3 4 1,5 6 Giovanni Guaraldi , James B